Effect of Hi-OxSR for the Treatment of Post COVID Condition

NCT06928506

Status	RECRUITING
Phase	Not Applicable
Sponsor	University Health Network, Toronto
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (8)

- Age e18 years;
- Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.
- Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.
- Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;
- Lingering symptoms from COVID-19 present at the time of randomization. "Lingering symptoms of Long COVID" must include self-reported cognitive dysfunction symptoms.

... and 3 more (see full listing online)

Exclusion (13)

- Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;
- Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;
- Contraindications to all of the study interventions;
- Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);
- Currently pregnant or breastfeeding.

... and 8 more (see full listing online)

Locations (3 total)

Kaye Edmonton Clinic, Edmonton, Alberta, Canada
University Health Network, Toronto, Ontario, Canada
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada